Avecho Biotechnology Ltd has released a press release.
AVE commences manufacturing for Phase III trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- Results of Entitlement Offer
- March 2023 Quarterly Activities Report & Appendix 4C
- Investor Presentation
- Prospectus
- Entitlement Offer to raise $11m for Phase 3 clinical trial
Later from Avecho Biotechnology
- Avecho licenses TPM for use in cancer drugs
- USPTO allows new TPM manufacturing patent
- AVE adds TPM cannabinoid gummies to portfolio
- AVE CBD capsule passes two-year stability milestone
- June 2023 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology